These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 25844963)

  • 1. Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis.
    Mosli MH; MacDonald JK; Bickston SJ; Behm BW; Tsoulis DJ; Cheng J; Khanna R; Feagan BG
    Inflamm Bowel Dis; 2015 May; 21(5):1151-9. PubMed ID: 25844963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vedolizumab for induction and maintenance of remission in ulcerative colitis.
    Bickston SJ; Behm BW; Tsoulis DJ; Cheng J; MacDonald JK; Khanna R; Feagan BG
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD007571. PubMed ID: 25105240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists.
    Feagan BG; Rubin DT; Danese S; Vermeire S; Abhyankar B; Sankoh S; James A; Smyth M
    Clin Gastroenterol Hepatol; 2017 Feb; 15(2):229-239.e5. PubMed ID: 27639327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vedolizumab for induction and maintenance of remission in Crohn's disease.
    Hui S; Sinopoulou V; Gordon M; Aali G; Krishna A; Ding NS; Boyapati RK
    Cochrane Database Syst Rev; 2023 Jul; 7(7):CD013611. PubMed ID: 37458279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis.
    Sandborn WJ; Baert F; Danese S; Krznarić Ž; Kobayashi T; Yao X; Chen J; Rosario M; Bhatia S; Kisfalvi K; D'Haens G; Vermeire S
    Gastroenterology; 2020 Feb; 158(3):562-572.e12. PubMed ID: 31470005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis.
    Feagan BG; Schreiber S; Wolf DC; Axler JL; Kaviya A; James A; Curtis RI; Geransar P; Stallmach A; Ehehalt R; Bokemeyer B; Khalid JM; O'Byrne S
    Inflamm Bowel Dis; 2019 May; 25(6):1028-1035. PubMed ID: 30365009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis.
    Jin Y; Lin Y; Lin LJ; Zheng CQ
    World J Gastroenterol; 2015 May; 21(20):6352-60. PubMed ID: 26034371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study.
    Motoya S; Watanabe K; Ogata H; Kanai T; Matsui T; Suzuki Y; Shikamura M; Sugiura K; Oda K; Hori T; Araki T; Watanabe M; Hibi T
    PLoS One; 2019; 14(2):e0212989. PubMed ID: 30807613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vedolizumab as induction and maintenance therapy for ulcerative colitis.
    Feagan BG; Rutgeerts P; Sands BE; Hanauer S; Colombel JF; Sandborn WJ; Van Assche G; Axler J; Kim HJ; Danese S; Fox I; Milch C; Sankoh S; Wyant T; Xu J; Parikh A;
    N Engl J Med; 2013 Aug; 369(8):699-710. PubMed ID: 23964932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis.
    Dulai PS; Singh S; Jairath V; Ma C; Narula N; Vande Casteele N; Peyrin-Biroulet L; Vermeire S; D'Haens G; Feagan BG; Sandborn WJ
    Aliment Pharmacol Ther; 2020 Feb; 51(4):435-445. PubMed ID: 31755121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
    Sands BE; Peyrin-Biroulet L; Loftus EV; Danese S; Colombel JF; Törüner M; Jonaitis L; Abhyankar B; Chen J; Rogers R; Lirio RA; Bornstein JD; Schreiber S;
    N Engl J Med; 2019 Sep; 381(13):1215-1226. PubMed ID: 31553834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methotrexate for induction of remission in refractory Crohn's disease.
    McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
    Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis.
    Sandborn WJ; Colombel JF; Panaccione R; Dulai PS; Rosario M; Cao C; Barocas M; Lasch K
    J Crohns Colitis; 2019 Feb; 13(2):172-181. PubMed ID: 30285104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of antitumour necrosis factor agents and vedolizumab in ulcerative colitis.
    Davis R; McParland P; Dodd S; Storey D; Probert C; Collins P; Skouras T; Steel A; Derbyshire E; Dibb M; Subramanian S
    Eur J Gastroenterol Hepatol; 2019 Jun; 31(6):661-667. PubMed ID: 30855421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis.
    Dignass AU; Siegmund B; Goertz R; Schneidewind G; Fanter L
    Scand J Gastroenterol; 2019 Feb; 54(2):178-187. PubMed ID: 30735443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis.
    Battat R; Ma C; Jairath V; Khanna R; Feagan BG
    Drug Saf; 2019 May; 42(5):617-632. PubMed ID: 30830573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humanized antibody to the alpha4beta7 integrin for induction of remission in ulcerative colitis.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2009 Jan; (1):CD007571. PubMed ID: 19160337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term Efficacy of Vedolizumab for Ulcerative Colitis.
    Loftus EV; Colombel JF; Feagan BG; Vermeire S; Sandborn WJ; Sands BE; Danese S; D'Haens GR; Kaser A; Panaccione R; Rubin DT; Shafran I; McAuliffe M; Kaviya A; Sankoh S; Mody R; Abhyankar B; Smyth M
    J Crohns Colitis; 2017 Apr; 11(4):400-411. PubMed ID: 27683800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PRISMA--efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials.
    Wang MC; Zhang LY; Han W; Shao Y; Chen M; Ni R; Wang GN; Wei FX; Zhang YW; Xu XD; Zhang YC
    Medicine (Baltimore); 2014 Dec; 93(28):e326. PubMed ID: 25526490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.